Hill, Andrew G.; Findlay, Michael P.; Burge, Matthew E.; Jackson, Christopher; Garcia Alfonso, Pilar; Samuel, Leslie; Ganju, Vinod; Karthaus, Meinolf; Amatu, Alessio; Tabernero, Josep
(American Association Cancer Research, 2018)
Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3.
Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI ...